Collection

2007 Spring ASEE Middle Atlantic Section Conference

Authors

L. Kuczynski; C. McGuinness; S. Farrell; B. G. Lefebvre; C. S. Slater

that we could examine.A confidentiality agreement was signed which limits the amount of information we can reveal 4about the drug and the manufacturing process. A cancer drug in the early stages of developmentwas selected. The team then met to set and review project goals/objectives. The initial part of the project involved a review of process development documentation and apilot plant visit to understand equipment issues. The basic data on raw materials, products,byproducts of the process were analyzed. Green engineering metrics for lab-scale (discovery),intermediate and pilot-scale processes were compared. Life cycle assessment was made usingoverall material and energy balances along